Evidence map›Paper›PMID 34746741›Full record

ArticleKidney medicine

Genomics Integration Into Nephrology Practice.

Filippo Pinto E Vairo, Carri Prochnow, Jennifer L Kemppainen, Emily C Lisi, Joan M Steyermark, Teresa M Kruisselbrink, Pavel N Pichurin, Rhadika Dhamija, Megan M Hager, Sam Albadri and 16 more

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Chronic kidney disease in children: an update.Clinical kidney journal · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

Filippo Pinto E VairoCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Carri ProchnowCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Jennifer L KemppainenCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Emily C LisiCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Joan M SteyermarkCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Teresa M KruisselbrinkCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Pavel N PichurinDepartment of Clinical Genomics, Mayo Clinic, Rochester, Minnesota.
Rhadika DhamijaDepartment of Clinical Genomics, Mayo Clinic, Scottsdale, Arizona.
Megan M HagerDepartment of Clinical Genomics, Mayo Clinic, Scottsdale, Arizona.
Sam AlbadriDepartment of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.
Lynn D CornellDepartment of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.
Konstantinos N LazaridisCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Eric W KleeCenter for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Sarah R SenumDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Mireille El TersDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Hatem AmerDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Linnea M BaudhuinDepartment of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.
Ann M MoyerDepartment of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.
Mira T KeddisDivision of Nephrology, Mayo Clinic, Scottsdale, Arizona.
Ladan ZandDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
David J SasDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Stephen B EricksonDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Fernando C FervenzaDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
John C LieskeDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Peter C HarrisDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota.
Marie C HoganDepartment of Clinical Genomics, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveThe etiology of kidney disease remains unknown in many individuals with chronic kidney disease (CKD). We created the Mayo Clinic Nephrology Genomics Clinic to improve our ability to integrate genomic and clinical data to identify the etiology of unexplained CKD. STUDY

designRetrospective study. SETTING &

participantsAn essential component of our program is the Nephrology Genomics Board which consists of nephrologists, geneticists, pathologists, translational omics scientists, and trainees who interpret the patient's clinical and genetic data. Since September 2016, the Board has reviewed 163 cases (15 cystic, 100 glomerular, 6 congenital anomalies of kidney and urinary tract (CAKUT), 20 stones, 15 tubulointerstitial, and 13 other). ANALYTICAL APPROACH: Testing was performed with targeted panels, single gene analysis, or analysis of kidney-related genes from exome sequencing. Variant classification was obtained based on the 2015 American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines.

resultsA definitive genetic diagnosis was achieved for 50 families (30.7%). The highest diagnostic yield was obtained in individuals with tubulointerstitial diseases (53.3%), followed by congenital anomalies of the kidney and urological tract (33.3%), glomerular (31%), cysts (26.7%), stones (25%), and others (15.4%). A further 20 (12.3%) patients had variants of interest, and variant segregation, and research activities (exome, genome, or transcriptome sequencing) are ongoing for 44 (40%) unresolved families. LIMITATIONS: Possible overestimation of diagnostic rate due to inclusion of individuals with variants with evidence of pathogenicity but classified as of uncertain significance by the clinical laboratory.

conclusionsIntegration of genomic and research testing and multidisciplinary evaluation in a nephrology cohort with CKD of unknown etiology or suspected monogenic disease provided a diagnosis in a third of families. These diagnoses had prognostic implications, and often changes in management were implemented.

Indexed as

Genomicsindividualized medicinenephrology

Identifiers

PMID34746741
PMCPMC8551494
OpenAlexW3176429212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.